Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Recent blog posts
Latest Hotspot
8 min read
DPP4 Biologics Sequence Review Report 2026: Dipeptidyl peptidase 4 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of DPP4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
DLL1 Biologics Sequence Review Report 2026: Delta-like protein 1 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of DLL1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
DDR2 Biologics Sequence Review Report 2026: Discoidin domain-containing receptor 2 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of DDR2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
DDR1 Biologics Sequence Review Report 2026: Epithelial discoidin domain-containing receptor 1 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of DDR1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CXCL12 Biologics Sequence Review Report 2026: Stromal cell-derived factor 1 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CXCL12 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CX3CL1 Biologics Sequence Review Report 2026: Fractalkine Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CX3CL1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN25 Biologics Sequence Review Report 2026: Claudin-25 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN25 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN24 Biologics Sequence Review Report 2026: Claudin-24 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN24 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN23 Biologics Sequence Review Report 2026: Claudin-23 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN23 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN22 Biologics Sequence Review Report 2026: Claudin-22 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN22 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN19 Biologics Sequence Review Report 2026: Claudin-19 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN19 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
Latest Hotspot
8 min read
CLDN17 Biologics Sequence Review Report 2026: Claudin-17 Similarity and Patent-Risk Signals
25 August 2026
A Biology Modality MCP review of CLDN17 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
<
1
2
3
4
5
>>
1139
>